Dr. Barry Dworkin

Availability of monoclonal antibody treatment for mild to moderate COVID is limited in Canada based on medication supply and availability of dedicated infusion centres and staff in some parts of the country.

Medical Mythbusting Commentary for October 26, 2021

Source:
Regeneron’s antibody COVID-19 treatment is popular in the U.S. — why not in Canada?
Doctors are often unaware of the only treatment for early Covid-19

Related posts:

  1. Interesting approach using monoclonal antibodies to treat Covid-19 infections. However clinical trials must follow to confirm in vitro findings.
  2. Will the COVID antiviral medications be the Thor’s Hammer against SARS-CoV-2 and help mitigate the ravages of the pandemic? These are impressive drugs but there are logistical, social, geographical, and financial caveats to solve in the process.
  3. PM Trudeau, your flouting of pandemic health policy rules demoralizes the country. Armchair “physicians”, stop flaunting cherry-picked preprint studies as “the” evidence HCQ works when there are just as many that refute it. That is why proper investigation and meta-analysis are required.
  4. Heparin seems to reduce progression of COVID-19 in hospitalized people with moderate symptoms but not for the critically ill. Study author states that more research required to find the therapeutic “sweet spot”.